Overview
Science Corp., the neurotechnology company founded by Max Hodak, has raised $230 million in a significant funding round to advance its neural interface platform. The company is building implantable devices designed to restore vision in patients with retinal degenerative diseases.
The Technology
Science Corp.'s flagship product is a retinal prosthesis that uses a flexible, high-density microelectrode array to interface directly with the retina. Combined with external camera and processing hardware, the system translates visual information into electrical signals the brain can interpret as sight.
Market Context
The raise positions Science Corp. as one of the most well-funded neural interface companies alongside Neuralink. The company's focus on a specific, high-impact clinical application — vision restoration — differentiates it from broader BCI platforms still searching for commercial product-market fit.
Capital Allocation
Funds will be directed toward clinical trials, manufacturing scale-up, and regulatory submissions targeting FDA breakthrough device designation.
